Connect with us


RD-Biotech Inaugurates its New Building in the Heart of Temis Santé

RD-Biotech’s new building was officially inaugurated this Friday evening in the heart of the Temis Santé technology park. Located on rue Françoise-Dolto, it is three times larger than the old premises, which had become too cramped due to the strong growth of the Bisonne company. The company was – and still is – very active by participating in the development of Pfizer’s Covid-19 vaccine.



This is an important moment for the Bisontinental flagship RD-Biotech, a laboratory that carries out R&D for clients in the biotechnology and pharmaceutical industries. The company, which was – and still is – very active during the health crisis by participating in the development of Pfizer’s Covid-19 vaccine, inaugurated its new building in the Hauts-du-Chazal sector on Friday, November 26th. “This is a response to the company’s growth in recent years,” says director Philippe Dulieu proudly, but modestly.

Born2Invest mobile app makes it easy for you to keep informed, to intuitively move from story to story, and from section to section. Our clean design lets you read articles without clutter, and use the app with no limits on how many articles you can view. Read more about RD-Biotech and get comprehensive access to global crowdfunding business, stock market, finance news, and trending topics with our companion app. 

3.5 million investment

The new establishment on rue Françoise-Dolto has certainly been invested since last April. But the health crisis delayed this symbolic moment in front of relatives and elected officials. The premises located on rue Henri-Baigue had indeed become too cramped for the manager, who created the company in 2002 with two partners. As the company grew, “we pushed the walls”, but “at a certain point, we decided to embark on this ambitious project. The result: in these new modern premises in the heart of the Temis Health Park, the surface area has been tripled to accommodate the 45 employees in 1,250 m². “We started this project in 2018,” continued the executive. The investment is $4 million (€3.5 million). […] Today, it’s a good step that we are taking, it allows us to take stock of where we are, and where we are going!” continued Philippe Dulieu.

All eyes are now on this other project: the construction of a 1,200 m² building not far from there. A “factory” intended for the production of DNA (GMP grade) to meet growing demand, and which should be the only production site of this type in France. This site has been selected as part of the France Recovery Plan. RD-Biotech hopes to hire about 15 people here within the next two years, “and even about 50 employees within 3-4 years.”


(Featured image by jarmoluk via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in L’EST, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Jeremy Whannell loves writing about the great outdoors, business ventures and tech giants, cryptocurrencies, marijuana stocks, and other investment topics. His proficiency in internet culture rivals his obsession with artificial intelligence and gaming developments. A biker and nature enthusiast, he prefers working and writing out in the wild over an afternoon in a coffee shop.